SCHEMBL19970864

SCHEMBL19970864

O=C(c1ccc2[nH]c(-c3cccnc3)nc2c1)N1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.51
JAK2 O60674 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
KIT P10721 3/20 0.45
HTT P42858 1/20 0.44
SLC6A7 Q99884 1/20 0.44
FAAH O00519 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
NAMPT P43490 1/20 0.43
MGLL Q99685 1/20 0.43
ACACB O00763 1/20 0.43
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970865 0.94 STAT3 (0.51) STAT3JAK2KDM4EALDH1A1MEN1
SCHEMBL19970858 0.92 NAMPT (0.52) STAT3JAK2MEN1KMT2AKIT
SCHEMBL19970750 0.91 MEN1 (0.53) STAT3KDM4EALDH1A1MEN1KMT2A
SCHEMBL19970839 0.89 KIT (0.49) KDM4EALDH1A1MAPTKITNAMPT
SCHEMBL19970859 0.86 NAMPT (0.52) STAT3MEN1KMT2ANAMPTACACB
SCHEMBL19970748 0.85 STAT3 (0.51) STAT3KDM4EALDH1A1MEN1KMT2A
SCHEMBL19970751 0.85 BCHE (0.55) STAT3KDM4EALDH1A1MEN1KMT2A
SCHEMBL19970736 0.85 SIGMAR1 (0.52) STAT3ALDH1A1MEN1KMT2AKIT
SCHEMBL19970841 0.84 RUNX1 (0.53) KDM4EALDH1A1MAPTKITHTT
SCHEMBL19970884 0.83 LSS (0.54) STAT3ALDH1A1LMNAHTTMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885JAK2 2299/4885KDM4E 1873/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885JAK2 2299/4885KDM4E 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.